Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- 20-Nov-2025
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded the state’s Medicaid program over alleged quality control lapses in a medicine to treat attention deficit hyperactivity disorder in children. Texas Attorney General Ken Paxton said on Wednesday the settlement resolves a November 2023 lawsuit accusing […]
Pfizer does deal with Trump to lower prescription drug prices
- 01-Oct-2025
WASHINGTON: Pfizer and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief. Trump also said Pfizer would offer that most-favored-nation pricing on all new drugs […]
Drugmakers racing to launch the first weight-loss pill
- 07-Aug-2025
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Both the GLP-1 weight loss drugs are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove […]
Drugmakers to raise prices of over 250 medicines starting Jan. 1
- 31-Dec-2024
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb’s cancer cell therapies and vaccines from France’s Sanofi (SNY) at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the drug price increases are below 10% […]
Danuglipron: Pfizer moves forward with once-daily weight-loss pill
- 11-Jul-2024
Pfizer has selected a preferred once-daily modified-release formulation for its weight loss candidate danuglipron, as the company looks to get ahead in the oral weight loss market. The company reached the preferred choice after an analysis of its ongoing Phase II pharmacokinetic study. Whilst several candidates showed encouraging data, one showed “the most favourable profile”, […]
Paxlovid fails as 15-day treatment for long COVID
- 08-Jun-2024
A 15-day course of Pfizer’s COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according to a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that […]
Canada approves Pfizer’s gene therapy for bleeding disorder
- 03-Jan-2024
Pfizer said on Wednesday that Canada’s health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B ahead of a U.S. decision. The approval was based on late-stage trials that showed a single dose of the therapy, to be sold under the brand name Beqvez, was superior to […]
Drugmakers set to raise prices on at least 500 drugs in January
- 30-Dec-2023
NEW YORK: Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors. Excluding different doses and formulations, more than 140 brands of drugs will have their prices raised next month, the […]
Pfizer gets OK for $43-billion Seagen deal
- 11-Dec-2023
Pfizer said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen later this week and plans to create a new oncology division that includes the acquisition early next year. Pfizer also said Chief Commercial Officer Angela Hwang would step down, and that it will split the its commercial business, […]
Paxlovid: Pfizer reveals price of COVID medicine
- 19-Oct-2023
Pfizer on Wednesday said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it. The new list price, which does not include rebates and other discounts […]